Evidence map›Paper›PMID 29431876›Full record

Observational studyEuropean journal of neurology2018

Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.

C Zecca, S Roth, O Findling, G Perriard, V Bachmann, M L Pless, A Baumann, C P Kamm, P H Lalive, A Czaplinski

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Observational
  5. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C ZeccaDepartment of Neurology, Neurocenter of Southern Switzerland, Regional Hospital Lugano (EOC), Lugano.
S RothNeurology Practice, Carouge, Geneva.
O FindlingDepartment of Neurology, Cantonal Hospital Aarau, Aarau.
G PerriardNovartis Pharma Schweiz AG, Rotkreuz.
V BachmannNovartis Pharma Schweiz AG, Rotkreuz.
M L PlessDepartment of Ophthalmology, Hospital of the Canton of Luzern, Luzern.
A BaumannNeurozentrum Oberaargau, Langenthal.
C P KammDepartment of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern.
P H LaliveDivision of Neurology, Department of Neurosciences, Faculty of Medicine, University Hospital of Geneva, Geneva.
A CzaplinskiNeurozentrum Bellevue, Zürich and Department of Neurology, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeIn 2011, fingolimod was approved in Switzerland for the treatment of relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to assess the effectiveness and retention of fingolimod in a real-life Swiss setting, in which patients can receive fingolimod as both first- and second-line treatment for RRMS.

methodsThis cross-sectional, observational study with retrospective data collection was performed at 19 sites that comprised both hospitals and office-based physicians across Switzerland. Sites were asked to document eligible patients in consecutive chronological order to avoid selection bias. Demographic and clinical data from 274 consenting adult patients with RRMS who had received treatment with fingolimod were analyzed.

resultsMean treatment duration with fingolimod was 32 months. Under fingolimod, 77.7% of patients remained free from relapses and 90.3% did not experience disability progression. The proportion of patients who were free from any clinical disease activity, i.e. without relapses and disability progression, was 72.1%. A total of 28.5% of patients had been RRMS treatment-naïve prior to fingolimod therapy. High long-term treatment retention rates ranging between 95.7% at 24 months and 87.8% at 36 months were observed.

conclusionIn this Swiss cohort of naïve and pre-treated subjects with RRMS, the majority of patients under fingolimod treatment showed freedom from relapses and disability progression. In addition, treatment retention rate over 2 and 3 years was high, irrespective of previous treatment.

Indexed as

AdultAgedCross-Sectional StudiesDisease ProgressionFemaleFingolimod HydrochlorideHumansImmunosuppressive AgentsMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingRetrospective StudiesSwitzerlandTreatment OutcomeYoung AdultFingolimod HydrochlorideImmunosuppressive Agentsfingolimodlong-term effectivenessmultiple sclerosisreal lifereal worldretentionSwitzerland

Identifiers

PMID29431876
PMCPMC5969089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.